Equity Profile

DBVT

DBV Technologies S.A.

Health CareBiotechnology$945.8M

Jul27Fri

Pre-Earnings Brief

UpcomingQ4-2024Pre-Market9:00 AM EDT

Company Snapshot

DBV Technologies S.A. is a biotechnology company focused on developing treatments for food allergies, particularly peanut allergies....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's market traction and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DBVT Q4-2024 Earnings Preview

Context

Company Snapshot

DBV Technologies S.A. is a biotechnology company focused on developing treatments for food allergies, particularly peanut allergies. As part of the health care sector, its innovations could significantly impact patient quality of life and market dynamics in allergy treatments.

Earnings Scorecard·Last 2Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+1.23%

Avg Stock Reaction

-1.28%

Last Quarter Recap

In Q3 2024, DBV Technologies reported an EPS of -$0.32, which was better than the expected -$0.38, resulting in a positive surprise. However, revenue details were not disclosed, leading to a modest stock increase of 1.25% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about DBV Technologies' upcoming earnings, especially after a slight EPS beat last quarter. However, the lack of revenue guidance raises concerns about overall performance.

Bull Case

If DBV can demonstrate strong demand for its products and improve its revenue outlook, it may lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could result in a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the revenue figures reveal about the demand for DBV's allergy treatments?

Revenue is crucial for understanding the company's market position and growth potential, especially in a competitive biotechnology landscape.

Will management provide any guidance on future product developments or market strategy?

Guidance on future plans can significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for DBV's products to gain traction in the market, especially given recent trends in allergy treatments.

Supporting Evidence

The company has shown a positive surprise in EPS recently, indicating better-than-expected performance.

The lack of revenue guidance may lead to overly cautious sentiment that doesn't reflect the company's actual market position.

Key Risk

If revenue shows unexpected growth, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to demonstrate tangible progress in its product offerings and market acceptance.

Bull Confirmed If

A revenue increase indicating strong market demand for allergy treatments would support a bullish outlook.

Bear Confirmed If

Failure to show any revenue growth or negative commentary on product uptake would confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

The options market is pricing in a potential 5% move in either direction following the earnings report.

Detail

30d HV

39.9%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DBV beats expectations and raises guidance, history suggests a potential stock increase of around 1.25%.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react moderately, reflecting investor caution.

Miss

A miss on earnings could lead to a decline of about 3.81%, as seen in previous quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product approvals or clinical trial results.
2Details on market demand for DBV's allergy treatments.
3Management's outlook on competitive pressures in the biotechnology space.
4Insights into cost management and operational efficiency.
5Any strategic partnerships or collaborations that may impact growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

CoStar Group, Inc.

Company Snapshot

DBV Technologies S.A. is a biotechnology company focused on developing treatments for food allergies, particularly peanut allergies....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's market traction and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DBVT Q4-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 2Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+1.23%

Avg Stock Reaction

-1.28%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If DBV can demonstrate strong demand for its products and improve its revenue outlook, it may lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could result in a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the revenue figures reveal about the demand for DBV's allergy treatments?

Revenue is crucial for understanding the company's market position and growth potential, especially in a competitive biotechnology landscape.

Will management provide any guidance on future product developments or market strategy?

Guidance on future plans can significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for DBV's products to gain traction in the market, especially given recent trends in allergy treatments.

Supporting Evidence

The company has shown a positive surprise in EPS recently, indicating better-than-expected performance.

The lack of revenue guidance may lead to overly cautious sentiment that doesn't reflect the company's actual market position.

Key Risk

If revenue shows unexpected growth, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to demonstrate tangible progress in its product offerings and market acceptance.

Bull Confirmed If

A revenue increase indicating strong market demand for allergy treatments would support a bullish outlook.

Bear Confirmed If

Failure to show any revenue growth or negative commentary on product uptake would confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

The options market is pricing in a potential 5% move in either direction following the earnings report.

Detail

30d HV

39.9%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DBV beats expectations and raises guidance, history suggests a potential stock increase of around 1.25%.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react moderately, reflecting investor caution.

Miss

A miss on earnings could lead to a decline of about 3.81%, as seen in previous quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product approvals or clinical trial results.
2Details on market demand for DBV's allergy treatments.
3Management's outlook on competitive pressures in the biotechnology space.
4Insights into cost management and operational efficiency.
5Any strategic partnerships or collaborations that may impact growth.